Lignes directrices de pratique clinique 2008 de l - Canadian ...

The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med. 1993;329:977-986.
43. The Diabetes Control and Complications Trial Research Group.
The effect of intensive diabetes treatment on the progression of
diabetic retinopathy in insulin-dependent diabetes mellitus. Arch
Ophthalmol. 1995;113:36-51.
44. The Diabetes Control and Complications Trial Research Group.
Early worsening of diabetic retinopathy in the Diabetes Control
and Complications Trial. Arch Ophthalmol. 1998;116:874-886.
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose
control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
46. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy
prevents the progression of diabetic microvascular complications
in Japanese patients with non-insulin-dependent diabetes mellitus:
a randomized prospective 6-year study. Diabetes Res Clin
Pract. 1995;28:103-117.
47. Klein R, Klein BEK, Moss SE, et al. Relationship of hyperglycemia
to the long-term incidence and progression of diabetic retinopathy.
Arch Intern Med. 1994;154:2169-2178.
48. Sivagnanam G. Rosiglitazone and macular edema. CMAJ. 2006;
175:276.
49. Kendall C, Wooltoroton E. Rosiglitazone (Avandia) and macular
edema. CMAJ. 2006;174:623.
50. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic
Study of Diabetic Retinopathy. XV. The long-term incidence of
macular edema. Ophthalmology. 1995;102:7-16.
51. Moss SE, Klein R, Klein BEK. Ten-year incidence of visual loss in
a diabetic population. Ophthalmology. 1994;101:1061-1070.
52. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications
in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
53. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive
blood pressure control in normotensive type 2 diabetic patients
on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:
1086-1097.
54. Miljanovic B, Glynn RJ, Nathan DM, et al. A prospective study
of serum lipids and risk of diabetic macular edema in type 1
diabetes. Diabetes. 2004;53:2883-2892.
55. Fonda GE. Optical treatment of residual vision in diabetic retinopathy.
Ophthalmology. 1994;101:84-88.
56. Bernbaum M, Albert SG. Referring patients with diabetes and
vision loss for rehabilitation: who is responsible? Diabetes Care.
1996;19:175-177.
57. Chew EY, Ferris FL III, Csaky KG, et al. The long-term effects of
laser photocoagulation treatment in patients with diabetic retinopathy:
the Early Treatment Diabetic Retinopathy Follow-up
Study. Ophthalmology. 2003;110:1683-1689.
58. The Diabetic Retinopathy Vitrectomy Study Research Group. Early
vitrectomy for severe vitreous hemorrhage in diabetic retinopa-
thy. Four-year results of a randomized trial: Diabetic Retinopathy
Study report 5. Arch Ophthalmol. 1990;108:958-964.
59. The Diabetic Retinopathy Vitrectomy Study Research Group.
Early vitrectomy for severe proliferative diabetic retinopathy
in eyes with useful vision. Results of a randomized trial—Diabetic
Retinopathy Vitrectomy Study report 3. Ophthalmology.
1988;95:1307-1320.
60. Smiddy WE, Flynn HW. Vitrectomy in the management of diabetic
retinopathy. Surv Ophthalmol. 1999;43:491-507.
61. Stolba U, Binder S, Gruber D, et al. Vitrectomy for persistent
diffuse macular edema. Am J Ophthalmol. 2005;140:295-301.
62. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal
hemorrhage in patients with diabetes mellitus.
Early Treatment Diabetic Retinopathy Study report no. 20. Arch
Ophthalmol. 1995;113:52-55.
63. Early Treatment Diabetic Retinopathy Study Research Group.
Effects of aspirin treatment on diabetic retinopathy. ETDRS
report number 8. Ophthalmology. 1991;98(5 suppl):757-765.
64. Chew EY, Benson WE, Remaley NA, et al. Results after lens
extraction in patients with diabetic retinopathy: Early Treatment
Diabetic Retinopathy Study report number 25. Arch Ophthalmol.
1999;117:1600-1606.
65. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II
randomized double-masked trial of pegaptanib, an anti-vascular
endothelial growth factor aptamer, for diabetic macular edema.
Ophthalmology. 2005;112:1747-1757.
66. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple
intravitreal injections of ranibizumab in patients with
center-involving clinically significant diabetic macular edema.
Ophthalmology. 2006;113:1706-1712.
67. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal
neovascularization after pegaptanib (Macugen) therapy in diabetic
individuals. Ophthalmology. 2006;113:23-28.
68. Grover D, Li J, Chong CW. Intravitreal steroid for macular edema
in diabetes. Cochrane Database Syst Rev. 2008;(1):CD0D5656.
69. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone
compared with macular laser grid photocoagulation for
the treatment of cystoid macular edema. Am J Ophthalmol.
2005;140;695-702.
70. Jonas JB, Kampperter BA, Harder B, et al. Intravitreal triamcinolone
acetonide for diabetic macular edema: a prospective, randomized
study. J Ocul Pharmacol Ther. 2006;22:200-207.
71. Sutter FK, Simpson JM, Gilles MC. Intravitreal triamcinolone for
diabetic macular edema that persists after laser treatment: threemonth
efficacy and safety results of a prospective, randomized,
double-masked, placebo-controlled clinical trial. Ophthalmology.
2004;111:2044-2049.
72. Pearson PA, Baker CW, Eliott D, et al. Fluocinolone acetonide
intravitreal implant for diabetic macular edema: 2 year results.
Association for Research in Vision and Ophthalmology Annual
Meeting; April 25-29, 2004; Fort Lauderdale, FL.
73. Pearson PA, Levy B, Comstock T. Fluocinolone acetonide Implant
| S153
cOMpLicatiOns et trOubLes cOMOrbides